STAMPEDE Trial Further Results - Adding Radiotherapy Can Benefit Some Patients Whose Prostate Cancer Has Spread

Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer. This result from the STAMPEDE trial was published, in open access format, in the PLOS Medicine journal, in early June. For more on this story, please click on the following link to the UCL News feed:


Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.